Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This randomized, single-dose, double-blind, double-dummy, four-period, four-sequence,
four-treatment, placebo and active controlled, comparative, multiple-center, crossover-design
bronchoprovocation study has been designed to evaluate the pharmacodynamic equivalence of
albuterol sulfate HFA inhalation aerosol, eq 90 mcg base (Amneal Ireland Limited) to PROAIR®
HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory, LLC) in
patients with stable mild asthma.